Magnesium L-Threonate

Magnesium L-Threonate acts at the intersection of magnesium physiology and NMDA receptor pharmacology, with the distinctive claim — supported primarily by rodent data — that L-threonate conjugation enables selective elevation of brain magnesium rather than only systemic serum magnesium.

The core magnesium pharmacology — NMDA receptor voltage block: Magnesium is a physiologically essential voltage-dependent blocker of the NMDA glutamate receptor. Under resting membrane potential, a magnesium ion occupies the NMDA channel pore and prevents ion flux even when glutamate is bound. When the postsynaptic neuron depolarizes (typically via AMPA receptor activation by nearby glutamate release), the membrane voltage change expels the magnesium from the pore, allowing calcium and sodium influx through the now-open NMDA channel. This voltage-dependent magnesium block is the fundamental biophysical mechanism that makes the NMDA receptor a coincidence detector — activating only when glutamate binding coincides with postsynaptic depolarization — which is the molecular basis of Hebbian synaptic plasticity, long-term potentiation (LTP), and much of experience-dependent learning. Magnesium availability at synaptic sites is therefore a rate-determining variable for LTP induction and for the balance between plasticity and excitotoxicity.

Why brain magnesium is hard to raise with conventional oral forms: Serum magnesium is tightly defended within a narrow physiological range by renal, bone, and intestinal regulation. Substantial oral dosing of conventional magnesium salts typically raises serum magnesium only modestly, and the blood-brain barrier (BBB) provides an additional regulatory step: magnesium transport into the CNS is mediated by specific transporters (including TRPM7 and members of the MagT1 family) that operate under homeostatic control. As a result, raising CSF or brain extracellular magnesium by oral supplementation is difficult to demonstrate with magnesium oxide, citrate, or even glycinate. This is the mechanistic gap that L-threonate was designed to address.

Slutsky et al. 2010 — the MIT brain-magnesium mechanism: Slutsky, Abumaria, Wu, Huang, Zhang, Li, Zhao, Govindarajan, Zhao, Tonegawa, Liu (Neuron PMID: 20152124) fed rats oral magnesium L-threonate and measured CSF magnesium, synaptic density, LTP induction thresholds, and behavioral learning performance. Unlike controls receiving standard magnesium salts, threonate-fed rats showed measurable CSF magnesium elevation, upregulated synaptic density in hippocampus and prefrontal cortex (including NR2B subunit expression), enhanced LTP at physiologic stimulation frequencies, and improved performance on learning and memory tasks — particularly pronounced in aged animals. The authors proposed that L-threonate functions as a carrier that enables magnesium transport across the BBB, though the exact molecular mechanism (whether threonate is directly transported with magnesium, whether threonate alters BBB permeability transiently, or whether it enables a slow-release depot of bioavailable magnesium) remains incompletely characterized. Abumaria et al. 2011 (PMID: 22016520) extended these findings to fear extinction models in rats, with magnesium L-threonate improving extinction learning — of theoretical relevance to anxiety and PTSD-like conditions.

Sun et al. 2016 — further brain magnesium elevation work: Sun et al. 2016provided additional rodent data examining brain magnesium elevation and downstream effects, supporting the basic premise that oral L-threonate can produce CNS magnesium changes that other oral magnesium forms do not.

NMDA receptor and synaptic density — the Slutsky hypothesis: The proposed sequence from elevated synaptic magnesium to cognitive improvement involves: (1) tonic reduction of NMDA receptor activity at baseline (the voltage-dependent block is more effective when magnesium is abundant) — reducing glutamate excitotoxicity under pathological conditions; (2) preservation of activity-dependent NMDA activation during strong coincident stimulation (the voltage expulsion of magnesium still occurs normally when needed for plasticity); (3) upregulation of synaptic density — more NMDA receptors and more synapses — as a compensatory homeostatic response to chronically elevated synaptic magnesium; (4) improved signal-to-noise ratio in synaptic plasticity — strong relevant stimuli can still drive plasticity, but low-level noise-like activation is more effectively filtered. The net behavioral prediction is improved learning and memory, particularly in aged brains where baseline synaptic density has declined.

Peripheral magnesium effects — the overlap with all Mg forms: In addition to proposed CNS-specific effects, magnesium L-threonate provides ~144-192mg elemental magnesium at typical 1.5-2g/day dosing. This elemental magnesium contributes to the standard peripheral magnesium physiology that applies to any magnesium supplement: cofactor for ~600 enzymatic reactions (particularly Mg-ATP), calcium channel antagonism in vascular smooth muscle (modest blood pressure lowering), neuromuscular relaxation (muscle cramps, restless legs), and GABA-A receptor modulation (mild anxiolytic and sleep effects). These peripheral benefits are not unique to threonate — they would be equivalent or greater with an equivalent elemental dose of magnesium glycinate or malate.

Pharmacokinetics — what we know and what we don't: Oral magnesium L-threonate is absorbed in the small intestine. Peak serum magnesium changes from typical Magtein dosing are modest. CSF magnesium elevation in humans has been less rigorously documented than in rats — most clinical support comes from behavioral/cognitive readouts in Liu 2016 rather than direct measurement of CSF magnesium. Threonate is a natural metabolite of ascorbic acid (vitamin C) that the body handles without known issues. Magnesium is excreted primarily by the kidneys; threonate is readily metabolized or excreted. No significant CYP450 interactions have been identified.

L-isomer specificity: The published research uses L-threonate — the stereoisomer naturally derived from L-ascorbic acid metabolism. D-threonate or racemic threonate mixtures have not been studied to the same degree. Magtein is specifically the L-threonate magnesium salt, and this stereochemical specificity is part of why Magtein-brand products are referenced specifically in the literature rather than generic "magnesium threonate."

Why claims about "smarter" or dramatic cognitive effects warrant skepticism: The human evidence base is one small industry-funded RCT (Liu 2016, n=44) with favorable but modest composite cognitive score improvements. This is not "take Magtein and become measurably smarter" territory — it is "in older adults with cognitive impairment, 12 weeks of Magtein produced statistically meaningful improvements on a composite cognitive outcome, relative to placebo, in a small trial funded by the manufacturer." Users should calibrate expectations accordingly. The Slutsky 2010 rat mechanism is strong, the translation to clinical human cognitive benefit in healthy younger users remains speculative, and independent replication of the Liu 2016 findings has been thin.

Magnesium L-Threonate is a proprietary chelated form of magnesium in which the magnesium cation is bound to L-threonic acid — a metabolite of ascorbic acid (vitamin C) — forming the salt commonly marketed under the brand name Magtein. It was developed in the mid-2000s by researchers associated with MIT (notably Guosong Liu, then at the MIT Department of Brain and Cognitive Sciences) with the explicit goal of producing a magnesium compound that could meaningfully raise brain magnesium concentrations in a way that ordinary oral magnesium salts (oxide, citrate, glycinate, malate, chloride) have historically struggled to accomplish. The resulting molecule was commercialized through Magceutics and Neurocentria, and Magtein is now the dominant ingredient in cognition-oriented magnesium products marketed to consumers.

The clinical rationale behind magnesium L-threonate rests on a specific biological problem: magnesium is a physiological NMDA glutamate receptor antagonist — a voltage-dependent blocker that sits in the NMDA channel pore and regulates excitatory neurotransmission — yet CNS magnesium concentrations are tightly defended and do not readily rise in response to oral supplementation with most common magnesium forms. Even substantial oral dosing of magnesium oxide or citrate (often 400mg elemental or more daily) may produce modest serum changes without corresponding cerebrospinal fluid (CSF) or brain extracellular magnesium elevation. This is not merely a theoretical concern — it implies that people using conventional magnesium supplements for cognitive, sleep, anxiety, or mood benefits may be relying partly on peripheral effects and on small central effects that are difficult to measure and potentially limited in magnitude. Slutsky et al. 2010 (Neuron PMID: 20152124) — the landmark MIT paper — demonstrated that L-threonate conjugation allows magnesium to raise brain magnesium concentrations in rats in a way that other forms did not, and that this elevation translated into upregulated synaptic density, enhanced LTP (long-term potentiation), and improved behavioral measures of learning and memory in aged animals. This rat paper remains the single most cited justification for preferring Magtein over other magnesium forms for cognitive applications.

Translated human evidence is substantially thinner than the mechanistic rat data. Liu et al. 2016 (Journal of Alzheimer's Disease) — the only decent human RCT published as of this writing — enrolled 44 older adults (ages 50-70) with cognitive impairment and randomized them to 12 weeks of Magtein (1.5-2 grams/day providing approximately 144-192mg elemental magnesium) or placebo. The trial reported improvements on a composite cognitive score that the authors interpreted as a reduction in "brain age" by approximately 9 years. Results were favorable but the study was small, industry-sponsored (funded by Magceutics), and independent replication has been weak — a point that matters for a supplement marketed with confident claims about cognition, memory, and "brain age." Users and practitioners should weigh that single decent RCT carefully: it is the most promising human data we have, but one small industry-funded trial is not a strong evidence base for the specific cognitive claims routinely made about Magtein in consumer marketing. Subsequent small trials have examined anxiety, sleep, and subjective cognitive symptoms with mixed and generally modest findings.

Why people actually take magnesium L-threonate in practice usually comes down to a few overlapping use cases: (1) cognitive support — particularly older adults or people concerned about age-related cognitive decline, based on Slutsky 2010 and Liu 2016; (2) sleep — evening dosing is commonly reported to improve subjective sleep quality, though this overlap substantially with non-specific benefits of magnesium repletion that are equally achievable with much cheaper Magnesium glycinate; (3) anxiety — systematic reviews of magnesium and anxiety (Pickering 2020) pool across many forms and find modest positive effects, but threonate-specific anxiety data are limited; (4) general magnesium repletion with a cognition halo — some users take Magtein as their primary magnesium source while hoping to capture both general repletion and specific CNS effects.

A practical point up front: Magtein delivers relatively little elemental magnesium per dose. The typical 1.5-2g/day Magtein dose provides ~144-192mg elemental magnesium — considerably less than a standard magnesium glycinate dose (200-400mg elemental at a fraction of the cost). For systemic magnesium repletion (muscle cramps, constipation, blood pressure, general wellness), glycinate is equivalent or superior and substantially cheaper. Magtein's proposed advantage is narrowly about CNS magnesium elevation for cognitive applications. Users often combine Magtein with another cheaper magnesium form to hit general elemental targets; relying on Magtein alone for both CNS and general repletion rarely pencils out.

The commercial landscape also warrants attention. "Magnesium threonate" products fall into two broad categories: Magtein-branded (certified through Magceutics/Neurocentria licensing, defined L-isomer specifications, third-party testing) and generic "magnesium threonate" (uncertain L-isomer purity, not studied in the published clinical research). The published evidence applies specifically to Magtein; this distinction is often glossed over in consumer marketing and price differences typically reflect it.

See also Magnesium, Lion's Mane, Creatine, Citicoline, Acetyl-L-Carnitine, Bacopa, Phosphatidylserine, and Fisetin for adjacent cognitive-support and magnesium-related compounds commonly used in nootropic stacks. This is educational content and not medical advice — magnesium supplementation is generally safe but clinical applications (particularly in renal impairment, in children, or with drug-interacting medications) warrant physician-level guidance.

IUPAC Name

Not yet available

CAS Number

Not yet available

Molecular Formula

Not yet available

Molecular Mass

Not yet available

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Get Magnesium L-Threonate Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Related Compounds

Related Articles

Data Completeness

Research Credibility